Chair
John Rasko, Head of Department, Cell & Molecular Therapies, Royal Prince Alfred Hospital
9am Presentation
Omer Butt, Vice President, Regulatory Affairs, CytoImmune Therapeutics
9.15am Fireside Chat: Leveraging CMC to Reduce Bottlenecks
- Role of process characterization in platform produced gene therapies
- Aligning with FDA guidance on platform technologies (section 2503)
Lucia Fernandez, Vice President Process Development & Manufacturing, VintaBio
9.30am Panel Discussion
Joined by all session participants and Miguel Forte, Chief Executive Officer, Kiji Therapeutics, President-Elect, ISCT